Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 7/2024

Inhalt (20 Artikel)

Open Access Research

Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data

Justin C. Moser, Shailender Bhatia, Asim Amin, Anna C. Pavlick, Keith A. Betts, Ella Xiaoyan Du, Tayla Poretta, Karishma Shelley, Swetha Srinivasan, Leon Alan Sakkal, Jennell Palaia, Maurice Lobo, Melanie Pe Benito, Joshua A. Linton, Yan Chen, Churong Xu, Lei Yin, Manasvi Sundar, Jeffrey Weber

Open Access Research

Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer

Yansong Liu, Mingcui Li, Zhengbo Fang, Shan Gao, Weilun Cheng, Yunqiang Duan, Xuelian Wang, Jianyuan Feng, Tianshui Yu, Jiarui Zhang, Ting Wang, Anbang Hu, Hanyu Zhang, Zhiyuan Rong, Suborna S. Shakila, Yuhang Shang, Fanjing Kong, Jiangwei Liu, Yanling Li, Fei Ma

Open Access Brief Report

Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy

Barbara Bailly-Caillé, Romain Levard, Diane Kottler, Anne Dompmartin, Jean-Matthieu L’Orphelin

Open Access Research

Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer

Panpan Zhang, Zhendong Chen, Si Shi, Zhiping Li, Feng Ye, Lijie Song, Yanqiao Zhang, Fei Yin, Xing Zhang, Jianming Xu, Ying Cheng, Weiguo Su, Michael Shi, Songhua Fan, Panfeng Tan, Chen Zhong, Ming Lu, Lin Shen

Open Access Research

Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study

Song Guan, Jifeng Sun, Yuan Wang, Sibei Han, Chen Chen, Dongsheng Yue, Yubei Huang, Kai Ren, Jun Wang, Jun Wang, Lujun Zhao

Open Access Research

Dual roles of HK3 in regulating the network between tumor cells and tumor-associated macrophages in neuroblastoma

Xin Wu, Tao Mi, Liming Jin, Chunnian Ren, Jinkui Wang, Zhaoxia Zhang, Jiayan Liu, Zhaoyin Wang, Peng Guo, Dawei He

Open Access Brief Report

Single-cell sequencing of tumour infiltrating T cells efficiently identifies tumour-specific T cell receptors based on the T cell activation score

Chaoting Zhang, Shance Li, Luyan Shen, Xia Teng, Yefei Xiao, Wenjun Yang, Zheming Lu

Open Access Research

Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study

Shengxiang Ren, Anwen Xiong, Jia Yu, Xicheng Wang, Baohui Han, Yueyin Pan, Jun Zhao, Yufeng Cheng, Sheng Hu, Tianshu Liu, Yalun Li, Ying Cheng, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Shegan Gao, Yongzhong Luo, Ying Liu, Caigang Liu, Huijie Duan, Shuni Wang, Xinfeng Yang, Jia Fan, Caicun Zhou

Open Access Research

The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis

Ya-Nan Jin, Meng-Yun Qiang, Ying Wang, Yu-Jing Lin, Ren-Wei Jiang, Wan-Wei Cao, Wang-Jian Zhang, Si-Yang Wang, Hong-Yu Zhang, Ji-Jin Yao

Open Access Research

Safety of immune checkpoint inhibitors in patients aged over 80 years: a retrospective cohort study

Tatsuki Ikoma, Toshihiko Matsumoto, Shogen Boku, Yusuke Motoki, Hidefumi Kinoshita, Hisashi Kosaka, Masaki Kaibori, Kentaro Inoue, Mitsugu Sekimoto, Takuo Fujisawa, Hiroshi Iwai, Makoto Naganuma, Hideaki Tanizaki, Yoji Hisamatsu, Hidetaka Okada, Takayasu Kurata

Open Access Research

Epigenetic silencing of LDHB promotes hepatocellular carcinoma by remodeling the tumor microenvironment

Peng Zhang, Yi Wan, Jinrong Ma, Jin Gong, Ziwei Zhong, Yuxin Cui, Hongli Zhang, Yanyan Da, Junpeng Ma, Chenxi Li, Lijuan Liu, Tian Gong, Youwen Tan, Chengsheng Zhang

Open Access Research

Evaluation of the antitumor effect of neoantigen peptide vaccines derived from the translatome of lung cancer

Fenbao Lian, Haitao Yang, Rujun Hong, Hang Xu, Tingting Yu, Gang Sun, Guanying Zheng, Baosong Xie

Open Access Research

GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration

Wenjing Zhao, Ziwei Liang, Yongshi Yao, Yang Ge, Guangyu An, Ling Duan, Jiannan Yao

Open Access Research

The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis

Ji-Bin Li, Ming-Yu Lai, Zhuo-Chen Lin, Wen-Long Guan, Yu-Ting Sun, Jing Yang, Wen-Xuan Wang, Zhi-Rong Yang, Miao-Zhen Qiu

Open Access Research

Effect of radiochemotherapy on peripheral immune response in glioblastoma

Léa Hampe, Susy Daumoine, Emeric Limagne, Nicolas Roussot, François Borsotti, Julie Vincent, Sylvia Ilie, Caroline Truntzer, François Ghiringhelli, Marion Thibaudin

Open Access Research

The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients

Yutaka Shimazu, Junya Kanda, Yoshiyuki Onda, Shin-ichi Fuchida, Kensuke Ohta, Yuji Shimura, Satoru Kosugi, Ryosuke Yamamura, Mitsuhiro Matsuda, Hitoshi Hanamoto, Yoko Adachi, Naoyuki Anzai, Masaaki Hotta, Kentaro Fukushima, Hideo Yagi, Satoshi Yoshihara, Yasuhiro Tanaka, Teruhito Takakuwa, Hirokazu Tanaka, Hirohiko Shibayama, Nobuhiko Uoshima, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Itaru Matsumura, Junya Kuroda, Akifumi Takaori-Kondo, Masayuki Hino

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.